Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COEP Coeptis Therapeutics	$8.40 -3.1%	$9.44	$2.31 ▼ $13.70	$29.52M	-0.59	118,051 shs	14,519 shs
CVM CEL-SCI	$2.37 -4.4%	$5.77	$1.98 ▼ $66.60	$7.19M	0.27	63,513 shs	110,362 shs
IPA ImmunoPrecise Antibodies	$0.73 +21.6%	$0.49	$0.27 ▼ $1.08	$33.40M	0.12	2.43 million shs	68.75 million shs
SXTC China SXT Pharmaceuticals	$2.04 +4.6%	$1.88	$0.95 ▼ $11.92	$30.87M	1.11	1.19 million shs	72,096 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COEP Coeptis Therapeutics	-5.14%	-8.54%	-12.42%	-17.03%	+49.59%
CVM CEL-SCI	+2.48%	+2.90%	-67.45%	-72.63%	-93.85%
IPA ImmunoPrecise Antibodies	-8.20%	+4.67%	+33.39%	+48.25%	-41.14%
SXTC China SXT Pharmaceuticals	-7.58%	+48.85%	-7.14%	-29.86%	-77.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COEP Coeptis Therapeutics	1.4063 of 5 stars	0.0	5.0	3.3	1.7	0.0
CVM CEL-SCI	0.071 of 5 stars	0.0	2.0	0.0	0.0	0.6
IPA ImmunoPrecise Antibodies	2.6615 of 5 stars	3.5	3.0	2.9	0.0	1.3
SXTC China SXT Pharmaceuticals	0.506 of 5 stars	0.0	3.0	2.4	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COEP Coeptis Therapeutics	2.00	Hold	N/A	N/A
CVM CEL-SCI	0.00	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	448.02% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CVM, COEP, SXTC, and IPA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/1/2025	IPA ImmunoPrecise Antibodies	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$3.00 ➝ $3.00
3/31/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
3/14/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COEP Coeptis Therapeutics	$62.87K	469.47	N/A	N/A	$0.48 per share	17.50
CVM CEL-SCI	N/A	N/A	N/A	N/A	$0.15 per share	N/A
IPA ImmunoPrecise Antibodies	$24.00M	1.39	N/A	N/A	$0.93 per share	0.78
SXTC China SXT Pharmaceuticals	$1.82M	17.76	N/A	N/A	$30.46 per share	0.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COEP Coeptis Therapeutics	-$21.27M	-$5.80	N/A	∞	N/A	N/A	-1,094.50%	-219.97%	N/A
CVM CEL-SCI	-$26.92M	-$12.61	N/A	N/A	N/A	N/A	-238.05%	-104.65%	N/A
IPA ImmunoPrecise Antibodies	-$20.13M	-$1.16	N/A	N/A	N/A	-114.50%	-73.74%	-42.68%	7/3/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest CVM, COEP, SXTC, and IPA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	COEP Coeptis Therapeutics	N/A	-$1.11	N/A	-$1.11	N/A	N/A
3/28/2025	Q3 2025	IPA ImmunoPrecise Antibodies	-$0.06	-$0.06	N/A	-$0.46	$6.59 million	$4.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
CVM CEL-SCI	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COEP Coeptis Therapeutics	0.03	0.40	0.40
CVM CEL-SCI	0.66	1.07	1.09
IPA ImmunoPrecise Antibodies	0.36	1.01	0.85
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COEP Coeptis Therapeutics	13.88%
CVM CEL-SCI	12.08%
IPA ImmunoPrecise Antibodies	6.70%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
COEP Coeptis Therapeutics	24.25%
CVM CEL-SCI	9.93%
IPA ImmunoPrecise Antibodies	6.83%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COEP Coeptis Therapeutics	2	3.51 million	2.46 million	Not Optionable
CVM CEL-SCI	43	3.03 million	64.67 million	Optionable
IPA ImmunoPrecise Antibodies	80	45.77 million	28.94 million	Not Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	3.90 million	Not Optionable

CVM, COEP, SXTC, and IPA Headlines

Recent News About These Companies

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.com

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.com

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

china sxt pharmaceuticals - SXTC

October 3, 2024 | foxbusiness.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Short Interest Report

October 2, 2024 | benzinga.com

Can China SXT Pharmaceuticals Inc (SXTC) Stock rise from its doldrums?

July 24, 2024 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock creates opportunities due to its volume and complexity

May 21, 2024 | bovnews.com

JAGX, BSGM and SXTC among mid-day movers

April 16, 2024 | msn.com

China SXT Pharmaceuticals Inc.

February 23, 2024 | wsj.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVM, COEP, SXTC, and IPA Company Descriptions

Coeptis Therapeutics NASDAQ:COEP

$8.40 -0.27 (-3.11%)

As of 03:59 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

CEL-SCI NYSE:CVM

$2.37 -0.11 (-4.44%)

As of 04:00 PM Eastern

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

ImmunoPrecise Antibodies NASDAQ:IPA

$0.73 +0.13 (+21.57%)

As of 04:00 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

China SXT Pharmaceuticals NASDAQ:SXTC

$2.04 +0.09 (+4.62%)

As of 04:00 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time